Absci’s Post

Sharing a podcast with our dynamic CEO enterpreneur, Sean McClain, and Luke Timmerman. Curious to learn about Absci and the future of AI drug discovery, then you should listen to it! #absci, #ai, #artificial intelligence, #drug discovery

Absci Senior Director of Alliance Management Fern M. will be speaking on a panel at the annual AUTM meeting next Monday. The panel will explore IP protection and commercialization of biological targets, various collaboration models for AI-based and traditional drug discovery companies, and more. We hope to see you there. https://lnkd.in/eTTqpbZY #AI #Biologics #GenerativeAI #DrugDiscovery

Ready to dive into the fascinating and transformative world of antibody discovery ? Let's dicover key techniques in antibody discovery ! 🔗 Read the full blog here: https://lnkd.in/eiAiNGi9 #Biologics #Hybridoma #SingleBCell #PhageDisplay #MonoclonalAntibodies #Biotechnology

𝗧𝗮𝗸𝗲 𝗼𝗻 𝘁𝗵𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲. Accurate prediction of antibody-antigen complex structure remains difficult even for the latest AlphaFold 3. Why is this the case? ◆ 𝗟𝗶𝗺𝗶𝘁𝗲𝗱 𝘁𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗱𝗮𝘁𝗮 𝗳𝗿𝗼𝗺 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗮𝘁𝗮 𝗕𝗮𝗻𝗸 (𝗣𝗗𝗕) ◆ 𝗛𝗶𝗴𝗵 𝘃𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻 𝗖𝗗𝗥-𝗛𝟯 ◆ 𝗔𝗯𝘀𝗲𝗻𝗰𝗲 𝗼𝗳 𝗰𝗼-𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗮𝗿𝘆 𝘀𝗶𝗴𝗻𝗮𝗹𝘀 𝗶𝗻 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗮𝗹𝗶𝗴𝗻𝗺𝗲𝗻𝘁𝘀 Despite these practical challenges, XtalFold, our proprietary structure modeling AI, has been successfully applied into dozens of antibody discovery projects. 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿, 𝗹𝗲𝘁'𝘀 𝗿𝗲𝘁𝗵𝗶𝗻𝗸 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘄𝗶𝘁𝗵 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗮𝗹 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀. Visit ailuxbio.com to explore next-generation applications inspired by XtalFold. #ailux #antibodies #ai #artificialintelligence #biologics #drugdiscovery #innovation 

Do you have FOMO? Don't worry, we got you. Message us now for the link to BOTH Live Webinar on Biological Breakthroughs highlighting key speakers Dr. Scott Martin MD MS and CEO Vivienne Reign. #biologics #drbizboom

Celebrating the British Science Week at Biologics in London, UK! Are you also attending the conference or in London during these days? Let's connect. Meet Cristiana Couto and Peter S. to explore how we can partner to propel your antibody projects towards success! Email us at info@fjbio.com or comment below to schedule a meeting! #BiologicsUK #BritishScienceWeek #antibodies #biologics #science

We're proud to be initiating IND-enabling studies on ABS-101, a de novo designed and optimized anti-TL1A antibody with a potential best-in-class profile. Find out more about how our de novo generative AI foundation model engineers epitope-specific antibodies to access novel biology and our AI lead optimization models further engineer candidates to have an optimal clinical development profile: https://lnkd.in/gvci5qK3 #AI #Biologics #GenerativeAI #DrugDiscovery

𝗘𝗻𝘃𝗶𝘀𝗶𝗼𝗻 𝘆𝗼𝘂𝗿 𝗽𝗼𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀: In a benchmark study to predict antibody-antigen complex structure, XtalFold outperforms AlphaFold-Multimer by a significant margin. ◆ 𝗛𝗶𝗴𝗵 𝗮𝗰𝗰𝘂𝗿𝗮𝗰𝘆: 70% prediction success rate ◆ 𝗛𝗶𝗴𝗵-𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝗽𝘂𝘁 𝗼𝗻𝗲-𝘀𝘁𝗲𝗽 𝗽𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗼𝗻: bypassing separate structure modeling and molecular docking steps ◆ 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝗻𝗲𝘄 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: accelerating hit generation and enabling next-gen engineering 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿, 𝗹𝗲𝘁'𝘀 𝘁𝘂𝗿𝗻 𝗽𝗼𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 𝗶𝗻𝘁𝗼 𝗿𝗲𝗮𝗹𝗶𝘁𝗶𝗲𝘀. Visit ailuxbio.com to learn how XtalFold is illuminating biologics discovery. #ailux #antibodies #ai #artificialintelligence #biologics #drugdiscovery #innovation 

We've developed IgDesign™, a powerful deep-learning method for antibody CDR design. With applications in de novo antibody design and lead optimization, IgDesign™ has the potential to help accelerate drug development and therapeutic antibody design projects. Highlights: - Experimentally validated AI model - Shown to design binders for 8 therapeutic antigens - Surpasses the performance of traditional methods Read the manuscript here: https://lnkd.in/gjEpSdTN #AI #Biologics #GenerativeAI #DrugDiscovery

Gregory Laurence's thought-provoking blog "From Pig Valves to Stem Cells" warrants a read by everyone seeking illumination on the seismic shifts in healthcare. His sagacious analysis interweaves medical marvels and market realities, unveiling this breakthrough field while detonating outdated models. As a member of the FPC's Project Liberty team, Dr. Laurence lauds regenerative medicine's formidable restorative powers, from reviving damaged organs to reversing lifelong knee pain. However, he laments the healthcare establishment, mired in old paradigms, beholden to special interests and increasingly hostile to profound innovation in patient care. Yet he finds hope in the inexorable advance of progress, the irrepressible human drive that impels medical game-changers to manifest once-unfathomable treatments. He spotlights the physician-entrepreneurs pioneering regenerative technologies as capitalism's torchbearers, disregarding calcified systems to directly deliver breakthrough care for patients. At once a sociological study and economic prophecy, this blog pulsates with zeal for the inevitable metamorphosis underway in healthcare. Laurence casts regenerative medicine not as a tide to passively watch rise, but a revolution that demands engagement now by doctors, investors and policymakers alike.